United Therapeutics Executive and Leadership Team

Harsh Hurkat, the Senior Analyst - Chief Financial Officer Org at United Therapeutics, directs financial analysis and organizational strategy. Overseeing fiscal operations, the Senior Analyst - Chief Financial Officer Org ensures robust financial planning and resource allocation to support the company's research and development initiatives. This leadership position involves rigorous budget management and the implementation of financial controls to maintain fiscal health. By analyzing market trends and economic indicators, Harsh Hurkat provides critical insights that inform strategic decision-making, driving sustainable growth and operational efficiency across the organization. The role demands meticulous attention to detail and a deep understanding of financial markets to optimize investment strategies and enhance shareholder value. Hurkat's contributions are essential for maintaining the financial integrity and long-term viability of United Therapeutics' innovative projects.

Michael Callahan, the President, UT Division of Cellular Therapeutics at United Therapeutics, leads the strategic direction and operational execution for the company's pioneering cellular therapy programs. Overseeing the development and commercialization of advanced cell-based treatments, the President, UT Division of Cellular Therapeutics drives innovation in regenerative medicine and complex biological therapies. This executive position involves managing cross-functional teams dedicated to scientific research, clinical translation, and manufacturing scale-up for novel cellular products. By fostering a culture of scientific excellence and rigorous quality control, Michael Callahan ensures that United Therapeutics remains at the vanguard of cellular therapeutics. Callahan's leadership is instrumental in advancing the company's mission to provide transformative treatments for patients with unmet medical needs, positioning United Therapeutics as a leader in this rapidly evolving field.

Michael Md Dtmh, the President, UT Division of Cellular Therapeutics at United Therapeutics, drives the strategic vision and operational management for the company's advanced cellular therapy division. Overseeing the entire lifecycle of cellular therapeutic development, the President, UT Division of Cellular Therapeutics ensures the successful translation of cutting-edge research into patient-ready treatments. This executive role involves leading teams focused on scientific innovation, clinical validation, and the complex manufacturing processes required for cellular therapies. By championing advancements in regenerative medicine, Michael Md Dtmh positions United Therapeutics at the forefront of this transformative field. Md Dtmh's leadership is essential for expanding access to novel therapies and achieving the company's goal of improving patient outcomes for severe diseases. The emphasis is on scientific rigor and scalable production.

Jeffrey Ross, the President at United Therapeutics, provides overarching leadership and strategic direction for the company's diverse operations. Overseeing key business units and driving corporate strategy, the President ensures alignment with the company's mission to develop life-saving therapies. This executive role involves guiding major initiatives, fostering cross-functional collaboration, and maintaining strong relationships with stakeholders across the biotechnology and pharmaceutical sectors. By championing innovation and operational excellence, Jeffrey Ross supports the advancement of United Therapeutics' pipeline of novel treatments. Ross's leadership is critical in navigating the complex landscape of drug development and commercialization, ensuring the company remains a leader in addressing critical unmet medical needs. The focus is on sustainable growth and impactful contributions to patient health.

Jeffrey Kase, the Vice President, Chief Information Officer at United Therapeutics, architects the company's technology infrastructure and digital transformation strategy. Overseeing all IT operations, the Vice President, Chief Information Officer ensures the secure and efficient management of data, systems, and networks critical to pharmaceutical research and manufacturing. This executive role involves leading the implementation of advanced technological solutions that enhance productivity and support the company's mission of developing life-saving therapies. By driving innovation in areas such as cybersecurity and data analytics, Jeffrey Kase safeguards sensitive information and optimizes operational workflows. Kase's leadership ensures that United Therapeutics remains at the forefront of technological advancement, enabling seamless collaboration and accelerating the delivery of critical medical treatments to patients globally. The focus remains on leveraging technology to achieve strategic business objectives and maintain a competitive edge in the biotechnology sector.

Gil Golden, the Chief Medical Officer at United Therapeutics, spearheads the company's clinical development and medical affairs strategies. Overseeing all clinical research programs, the Chief Medical Officer ensures the rigorous scientific evaluation and ethical conduct of studies aimed at bringing innovative therapies to patients. This critical role involves guiding the translation of scientific discoveries into viable treatment options, managing regulatory interactions, and fostering relationships with the medical community. By directing the medical team, Gil Golden ensures that clinical trial designs are robust and that data generated meets the highest standards of scientific integrity. Golden's expertise is fundamental to advancing the company's pipeline of novel pharmaceuticals and cellular therapeutics, ultimately impacting patient outcomes and shaping the future of medicine. The focus is on evidence-based medicine and patient-centric approaches to drug development.

Alyssa Friedrich, the Executive Vice President & Chief People Officer at United Therapeutics, directs the comprehensive human capital strategy and organizational development initiatives. Overseeing all aspects of talent management, employee relations, and corporate culture, the Executive Vice President & Chief People Officer cultivates a high-performance environment that supports the company's groundbreaking work in biotechnology. This leadership role involves attracting, retaining, and developing top talent essential for advancing life-saving therapies. By championing employee engagement and fostering a diverse and inclusive workplace, Alyssa Friedrich ensures that United Therapeutics remains an employer of choice. Friedrich's strategic vision is crucial for aligning people operations with the company's mission, driving innovation, and ensuring the well-being and professional growth of the entire workforce. The focus is on building a resilient and motivated team capable of tackling complex scientific challenges.

Marc Lorber, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC at United Therapeutics, directs the clinical strategy and medical oversight for lung-focused biotechnology initiatives. Overseeing the design and execution of clinical trials, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC ensures the rigorous evaluation of novel therapies targeting pulmonary diseases. This leadership role involves guiding the medical aspects of drug development, from early-stage research through regulatory submission and post-market surveillance. By collaborating with research teams and external medical experts, Marc Lorber advances the company's pipeline of innovative treatments for lung conditions. Lorber's expertise is critical in translating scientific advancements into tangible patient benefits, reinforcing United Therapeutics' commitment to addressing significant unmet medical needs in respiratory health. The focus is on evidence generation and patient safety.